Top Biotech Stocks To Invest In 2019

Michael A. Robinson

When it comes to biotech, Wall Street tends to overreact. Though there’s no reason for it to be there, biotech is in the dog house, and investors have been conditioned to punish the sector and its stocks whenever the opportunity presents itself.

You see, there are three main reasons biotech is down: Wall Street is worried about high and rising drug prices, the impact of a possible trade war on foreign sales, and expiring patents for some older medications.

Over the last several years, for example, I’ve read a number of Wall Street reports about the so-called “biotech patent cliff.” Simply stated, a drug falls off that “cliff” when its patent runs out and it starts facing competition from generics.

And a number of successful drugs out there are rapidly approaching their patent cliffs.

Top Biotech Stocks To Invest In 2019: iShares Nasdaq Biotechnology Index Fund(IBB)

Advisors’ Opinion:

  • [By Jim Crumly]

    Biotech shares soared on good news from clinical trials; the iShares NASDAQ Biotechnology ETF (NASDAQ:IBB) gained 3.8%. The tech sector also had a big day, with the Technology Select Sector SPDR ETF (NYSEMKT:XLK) jumping 1.2%.

  • [By Jim Crumly]

    Biotech stocks surged, with the iShares NASDAQ Biotechnology ETF (NASDAQ:IBB) rising 1.8%. The retail sector was weak; the SPDR S&P Retail ETF (NYSEMKT:XRT) slipped 0.7%. 

  • [By Dan Caplinger]

    For those who prefer not to try to pick individual stocks, exchange-traded funds can be a valuable alternative. In particular, the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) offers a diversified portfolio of biotech stocks that gives you complete coverage of the sector. Since going through a major downturn in 2015 and early 2016, the biotech sector has bounced back. With that in mind, let’s take a closer look at the iShares biotech ETF to see whether it would make a smart buy right now.

  • [By Brian Feroldi, Keith Speights, and Sean Williams]

    The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) — which is an exchange-traded fund that holds nearly 200 biotech stocks — has drastically underperformed the S&P 500 over the last three years. That fact suggests that there are bargains to be found in the biotech space.

Top Biotech Stocks To Invest In 2019: Catalent, Inc.(CTLT)

Advisors’ Opinion:

  • [By Logan Wallace]

    SG Americas Securities LLC decreased its holdings in shares of Catalent (NYSE:CTLT) by 19.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,152 shares of the company’s stock after selling 7,832 shares during the quarter. SG Americas Securities LLC’s holdings in Catalent were worth $1,320,000 as of its most recent SEC filing.

  • [By Max Byerly]

    Catalent (NYSE:CTLT) SVP Steven L. Fasman sold 2,252 shares of the firm’s stock in a transaction on Wednesday, June 20th. The shares were sold at an average price of $41.78, for a total transaction of $94,088.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Catalent (CTLT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Catalent (CTLT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Catalent Inc (NYSE:CTLT) – Investment analysts at Piper Jaffray Companies reduced their Q2 2019 earnings per share (EPS) estimates for Catalent in a research note issued on Tuesday, August 28th. Piper Jaffray Companies analyst S. Wieland now anticipates that the company will post earnings of $0.36 per share for the quarter, down from their prior forecast of $0.42. Piper Jaffray Companies also issued estimates for Catalent’s Q3 2019 earnings at $0.40 EPS, Q4 2019 earnings at $0.68 EPS and FY2019 earnings at $1.71 EPS.

  • [By Motley Fool Transcribers]

    Catalent Inc  (NYSE:CTLT)Q2 2019 Earnings Conference CallFeb. 05, 2019, 8:15 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top Biotech Stocks To Invest In 2019: ProQR Therapeutics N.V.(PRQR)

Advisors’ Opinion:

  • [By Stephan Byrd]

    ProQR Therapeutics (NASDAQ:PRQR) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.15, Zacks reports.

  • [By Logan Wallace]

    Press coverage about ProQR Therapeutics (NASDAQ:PRQR) has trended somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ProQR Therapeutics earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.796201369253 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

  • [By Brian Feroldi]

    After reporting data from a phase 1/2 clinical trial, shares of ProQR Therapeutics N.V. (NASDAQ:PRQR), a clinical-stage biotech focused on RNA medicines that treat rare genetic diseases, rose 70% as of 12:13 p.m. EDT on Wednesday.

  • [By Chris Lange]

    ProQR Therapeutics N.V. (NASDAQ: PRQR) shares made a massive gain early on Wednesday after the firm announced positive interim results from its Phase 1/2 clinical trial of QR-110 in patients with Leber’s congenital amaurosis 10 (LCA10).

  • [By Keith Speights]

    Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) were up 16% as of 3:48 p.m. EDT on Monday. ProQR didn’t report any new announcements, but the biotech’s update last Wednesday from a phase 1/2 clinical study — of RNA medicine QR-110, in treating Leber congenital amaurosis type 10 (LCA10) — still had investors fired up.

  • [By Keith Speights]

    Three of the biggest winners were ProQR Therapeutics (NASDAQ:PRQR), MannKind Corp. (NASDAQ:MNKD), and Arrowhead Pharmaceuticals (NASDAQ:ARWR). Here’s why these biotech stocks soared this week and a look at whether they’re smart picks for investors now.

Leave a Reply

Your email address will not be published. Required fields are marked *